Cost-Effectiveness Analysis of Revaccination Against Pertussis in Preschool Children
https://doi.org/10.15690/vsp.v18i6.2068
Abstract
Foreign practices of cost-effectiveness analysis of revaccination against pertussis in preschool children, teenagers and adults are presented. The economic viability of the second revaccination against pertussis at preschool/early-school age is shown: it can reduce both direct and indirect expenses associated with pertussis not only in revaccinated groups but also in infants due to increasing of population immunity. International guidelines on the implementation of revaccination against pertussis through replacing of exhausted diphtheria tetanus modified vaccine on DTaP within the framework of the national vaccination schedule.
Keywords
children,
pertussis,
revaccination,
DTaP,
cost-effectiveness,
direct expense,
indirect expenses,
vaccination,
national vaccination schedule
Supporting agencies: Not specified
About the Authors
Irina V. Mikheeva
Central Research Institute of Epidemiology
Russian Federation
Disclosure of interest: receives fees for lecturing from “Sanofi Pasteur” company
Russian Federation
Moscow
Disclosure of interest: receives fees for lecturing from “Sanofi Pasteur” company
Marina A. Mikheeva
Central Research Institute of Epidemiology
Russian Federation
Disclosure of interest: confirmed the absence of a reportable conflict of interests
Russian Federation
Moscow
Disclosure of interest: confirmed the absence of a reportable conflict of interests
References
1. WHO. Weekly epidemiological record. Pertussis vaccines: WHO position paper — August 2015 [Internet]. [cited 2015 August 28] Available from: http://www.who.int/entity/wer/2015/wer9035.pdf.
2. Mikheeva IV, Saltykova TS, Mikheeva MA. Expediency and prospects of a vaccinal preventionof whooping cough without age restrictions. Jurnal infektologii. 2018;10(4):14-23. (In Russ). doi: 10.22625/2072-6732-2018-10-4-14-23.
3. Wright SW, Edwards KM, Decker M, Zeldin MH. Pertussis infection in adults with persistent cough. JAMA. 1995;273(13):1044-1046. doi: 10.1001/jama.273.13.1044.
4. Rospotrebnadzor RF. State report «O sostoyanii sanitarno-epidemiologicheskogo blagopoluchiya naseleniya v Rossiyskoy Federatsii v 2018 godu”. Moscow: Federal service for supervision of consumer protection and human welfare; 2018. 220 р. (In Russ).
5. Rospotrebnadzor RF. Infektsionnaya zabolevayemost’ v Rossiyskoy Federatsii za yanvar’-oktyabr’ 2018 g. Svedeniya ob infektsionnykh i parazitarnykh zabolevaniyakh za yanvar’-dekabr’ 2018 g. (In Russ). Доступно по: http://www.rospotrebnadzor.ru/activities/statistical-materials/statictic_details.php?ELEMENT_ID=10897. Ссылка активна на 14.01.2019.
6. Namazova L, Gevorkyan A, Galeeva E. Is pertussis a problem for the Russian pediatrics? Can we overcome it? Pediatric pharmacology. 2006;3(4):6-9. (In Russ).
7. Celentano LP Massari M, Paramatti D, et al. Resurgence of pertussis in Europe. Pediatr Infect Dis J. 2005;24(9):761-765. doi: 10.1097/01.inf.0000177282.53500.77.
8. Cherry JD. The epidemiology of pertussis: a comparison of the epidemiology of the disease pertussis with the epidemiology of Bordetella pertussis infection. Pediatrics. 2005;115(5): 1422-1427. doi: 10.1542/peds.2004-2648.
9. Sheridan SL, Frith K, Snelling TL, et al. Waning vaccine immunity in teenagers primed with whole cell and acellular pertussis vaccine: recent epidemiology. Expert Rev Vaccines. 2014;13(9):1081-1106. doi: 10.1586/14760584.2014.944167.
10. Dalby T, Andersen PH, Hoffmann S. Epidemiology of pertussis in Denmark, 1995 to 2013. Euro Surveill. 2016;21(36). doi: 10.2807/1560-7917.ES.2016.21.36.30334.
11. WHO. WHO vaccine-preventable diseases: monitoring system. 2019 global summary [Internet]. [cited 2019 Dec 10]. Available from: http://apps.who.int/immunization_monitoring/globalsummary/schedules.
12. Hellenbrand W, Beier D, Jensen E, et al. The epidemiology of pertussis in Germany: past and present. BMC Infect Dis. 2009;9:22. doi: 10.1186/1471-2334-9-22.
13. Berti E, Chiappini E, Orlandini E, et al. Pertussis is still common in a highly vaccinated infant population. Acta Paediatr. 2014;103(8): 846-849. doi: 10.1111/apa.12655.
14. De Greeff SC, Mooi FR, Westerhof A, et al. Pertussis disease burden in the household: how to protect young infants. Clin Infect Dis. 2010;50(10):1339-1345. doi: 10.1086/652281.
15. Auger KA, Patrick SW, Davis MM. Infant hospitalizations for pertussis before and after Tdap recommendations for adolescents. Pediatrics. 2013;132(5):e1149-1155. doi: 10.1542/peds.2013-1747.
16. Haller S, Dehnert M, Karagiannis I, et al. Effectiveness of routine and booster pertussis vaccination in children and adolescents, federal state of Brandenburg, Germany, 2002-2012. Pediatr Infect Dis J. 2015;34(5):513-519. doi: 10.1097/INF.0000000000000654.
17. Lee GM, Lebaron C, Murphy TV, et al. Pertussis in adolescents and adults: should we vaccinate? Pediatrics. 2005;115(6): 1675-1684. doi: 10.1542/peds.2004-2509.
18. Quinn HE, McIntyre PB. The impact of adolescent pertussis immunization, 2004-2009: Lessons from Australia. Bull World Health Organ. 2011;89(9):666-674. doi: 10.2471/BLT.11.086538.
19. Masseria C, Martin CK, Krishnanajah G, et al. Incidence and burden of pertussis among infants less than 1 year of age. Pediatr Infect Dis J. 2017;36(3):e54-e61. doi: 10.1097/INF.0000000000001440.
20. Berger JT, Villalobos ME, Clark AE, et al. Cognitive development one year after infantile critical pertussis. Pediatr Crit Care Med. 2018;19(2):89-97. doi: 10.1097/PCC.0000000000001367.
21. Wang K, Fry NK, Campbell H. Whooping cough in school age children presenting with persistent cough in UK primary care after introduction of the preschool pertussis booster vaccination: prospective cohort study. BMJ. 2014;348:g3668. doi: 10.1136/bmj.g3668.
22. Van Hoek AJ, Campbell H, Andrews N, et al. The burden of disease and health care use among pertussis cases in school aged children and adults in England and Wales; a patient survey. PLoS One. 2014;9(11):e111807. doi: 10.1371/journal.pone.0111807.
23. Rothstein E, Edwards K. Health burden of pertussis in adolescents and adults. Pediatr Infect Dis J. 2005;24(5 Suppl):S44-47. doi: 10.1097/01.inf.0000160912.58660.87.
24. Kim TH, Johnstone J, Loeb M. Vaccine herd effect. Scand J Infect Dis. 2011;43(9):683-689. doi: 10.3109/00365548.2011.582247.
25. O'Brien JA, Caro JJ. Hospitalization for pertussis: profiles and case costs by age. BMC Infect Dis. 2005;5:57. doi: 10.1186/1471-2334-5-57.
26. Lee GM, Lett S, Schauer S, et al. Societal costs and morbidity of pertussis in adolescents and adults. Clin Infect Dis. 2004; 39(11):1572-1580. doi: 10.1086/425006.
27. Buck PO, Meyers JL, Gordon LD, et al. Economic burden of diagnosed pertussis among individuals with asthma or chronic obstructive pulmonary disease in the USA: an analysis of administrative claims. Epidemiol Infect. 2017;145(10):2109-2121. doi: 10.1017/S0950268817000887.
28. Caro JJ, Getsios D, El-Hadi W, et al. Pertussis immunization of adolescents in the United States: an economic evaluation. Pediatr Infect Dis J. 2005;24(5 Suppl):S75-82. doi: 10.1097/01.inf.0000160918.72953.51.
29. Varan AK, Harriman KH, Winter K, et al. Economic and social impact of pertussis among adolescents in San Diego county. J Adolesc Health. 2016;58(2):241-244. doi: 10.1016/j.jado-health.2015.10.012.
30. McLaughlin JM, McGinnis JJ, Tan L, et al. Estimated human and economic burden of four major adult vaccine-preventable diseases in the United States, 2013. J Prim Prev. 2015;36(4):259-273. doi: 10.1007/s10935-015-0394-3.
31. Lee LH, Pichichero ME. Costs of illness due to Bordetella pertussis in families. Arch Fam Med. 2000;9(10):989-996. doi: 10.1001/archfami.9.10.989.
32. Purdy KW, Hay JW, Botteman MF, Ward JI. Evaluation of strategies for use of acellular pertussis vaccine in adolescents and adults: a cost-benefit analysis. Clin Infect Dis. 2004;39(1):20-28. doi: 10.1086/421091.
33. Edmunds WJ, Brisson M, Melegaro A, Gay NJ. The potential cost-effectiveness of acellular pertussis booster vaccination in England and Wales. Vaccine. 2002;20(9-10):1316-1330. doi: 10.1016/s0264-410x(01)00473-x.
34. Stevenson M, Beard S, Finn A, Brennan A. Estimating the potential health gain and cost consequences of introducing a pre-school DTPa pertussis booster into the UK child vaccination schedule. Vaccine. 2002;20(13-14):1778-1786. doi: 10.1016/s0264-410x(02)00025-7.
35. De Greeff SC, Lugner AK, van den Heuvel DM, et al. Economic analysis of pertussis illness in the Dutch population: implications for current and future vaccination strategies. Vaccine. 2009; 27(13):1932-1937. doi: 10.1016/j.vaccine.2009.01.106.
36. Paulden M. Recent amendments to NICE's value-based assessment of health technologies: implicitly inequitable? Expert Rev Pharmacoecon Outcomes Res. 2017;17(3):239-242. doi: 10.1080/14737167.2017.1330152.
37. Reckers-Droog VT, van Exel NJ, Brouwer WB. Looking back and moving forward: on the application of proportional shortfall in healthcare priority setting in the Netherlands. Health Policy. 2018;122(6):621-629. doi: 10.1016/j.healthpol.2018.04.001.
38. Rodriguez-Cobo I, Chen YF, Olowokure B, Litchfield I. Clinical and economic assessment of different general population strategies of pertussis vaccine booster regarding number of doses and age of application for reducing whooping cough disease burden: a systematic review. Vaccine. 2008;26(52):6768-6776. doi: 10.1016/j.vaccine.2008.09.042.
39. Millier A, Aballea S, Annemans L, et al. A critical literature review of health economic evaluations in pertussis booster vaccination. Expert Rev Pharmacoecon Outcomes Res. 2012;12(1):71-94. doi: 10.1586/erp.11.94.
40. [Pertussis vaccines: WHO position paper. (In English, French)]. Wkly Epidemiol Rec. 2010;85(40):385-400.
41. Mikheeva IV, Fomkina NN, Mikheeva MA. Modern epidemiological and economic characteristicsof whooping cough in Moscow. Jurnal infektologii. 2019;11(1):84-91. (In Russ).]doi: 10.22625/2072-6732-2019-11-1-84-91.
42. CDC. Table 1. Recommended child and adolescent immunization schedule for ages 18 years or younger, United States, 2019 [Internet]. [cited 2019 February 8] Available at: https://www.cdc.gov/vaccines/schedules/hcp/child-adolescent.html.
43. [Diphtheria vaccine: WHO position paper — August 2017. (In English, French)]. Wkly Epidemiol Rec. 2017;92(31):417-435.
44. Maman K, Zollner Y, Greco D, et al. The value of childhood combination vaccines: from beliefs to evidence. Hum Vaccin Immun. 2015;11(9):2132-2141. doi: 10.1080/21645515.2015.1044180.
45. Coudeville L, van Rie A, Getsios D, et al. Adult vaccination strategies for the control of pertussis in the United States: an economic evaluation including the dynamic population effects. PLoS One. 2009;4(7):e6284. doi: 10.1371/journal.pone.0006284.
Review
For citations:
Mikheeva I.V., Mikheeva M.A. Cost-Effectiveness Analysis of Revaccination Against Pertussis in Preschool Children. Current Pediatrics. 2019;18(6):470-477. (In Russ.) https://doi.org/10.15690/vsp.v18i6.2068
Views:
1004
Email this article 
